stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Current ratio
Harmony Biosciences Holdings, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 3.4×, down 0.2× from fiscal 2025 (3.6×). Over the past ten years it has ranged from 1.6× (fiscal 2019) to 12.0× (fiscal 2018); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of 5.0× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.6× | 8.73% |
| FY2024 | 3.3× | 20.13% |
| FY2023 | 2.8× | (45.72%) |
| FY2022 | 5.1× | (4.07%) |
| FY2021 | 5.3× | 170.70% |
| FY2020 | 2.0× | 23.41% |
| FY2019 | 1.6× | (86.79%) |
| FY2018 | 12.0× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 3.4× | (1.04%) |
| Jun 2026 | 3.5× | (2.91%) |
| Mar 2026 | 3.6× | (0.39%) |
| Dec 2025 | 3.6× | (4.19%) |
| 24 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | 37.3× |
| MAZE Maze Therapeutics, Inc. compare | 18.3× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 9.2× |
| REPL Replimune Group, Inc. compare | 7.1× |
| VIR Vir Biotechnology, Inc. compare | 6.3× |
| SRPT Sarepta Therapeutics, Inc. compare | 3.5× |
| HRMY Harmony Biosciences Holdings, Inc. | 3.4× |
| MESO Mesoblast Limited compare | 1.6× |
| FTRE Fortrea Holdings Inc. compare | 1.0× |
| Biotechnology industry median | 5.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)